Relmada Therapeutics (OTCMKTS:RLMD) Cut to “Hold” at ValuEngine

Relmada Therapeutics (OTCMKTS:RLMD) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report released on Thursday, ValuEngine reports.

RLMD stock traded up $0.01 during mid-day trading on Thursday, reaching $2.20. 25,610 shares of the company traded hands, compared to its average volume of 25,182. Relmada Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $3.42. The company has a 50 day simple moving average of $2.01.

Relmada Therapeutics (OTCMKTS:RLMD) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.09) earnings per share (EPS) for the quarter.

In related news, Director Paul Edward Kelly purchased 100,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $150,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.10% of the stock is currently owned by insiders.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.

Featured Story: What is a Fiduciary?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with's FREE daily email newsletter.